Prehospital administration of P2Y12 inhibitors and early coronary reperfusion in primary PCI: An observational comparative study

Thrombosis and Haemostasis

Volumn 114, Issue 3, 2015, Pages 623-631

  De Backer, Ole ^a   Ratcovich, Hanna ^a   Biasco, Luigi ^a   Pedersen, Frants ^a   Helqvist, Steffen ^a   Saunamaki, Kari ^a   Tilsted, Hans Henrik ^a   Clemmensen, Peter ^a   Olivecrona, Goran ^a   Kelbaek, Henning ^a   Jørgensen, Erik ^a   Engstrøm, Thomas ^a   Holmvang, Lene ^a  

^a University of Copenhagen   (Denmark)

Author keywords

Antiplatelet therapy; Coronary reperfusion; Pretreatment; ST elevation myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; PRASUGREL; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ADULT; ANGIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; COMPARATIVE STUDY; CORONARY REPERFUSION; FEMALE; HEART DISEASE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; BLOOD; CORONARY ANGIOGRAPHY; CORONARY ARTERY BLOOD FLOW; DRUG ADMINISTRATION; DRUG EFFECTS; EMERGENCY HEALTH SERVICE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; TIME FACTOR; TREATMENT OUTCOME;

ADENOSINE; AGED; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; DRUG ADMINISTRATION SCHEDULE; EMERGENCY MEDICAL SERVICES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84940652937     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-01-0026     Document Type: Article

References (21)

1. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569–2619
2. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61: 78–140
3. Wiviott SD, Braunwald E, McCabe CH, et al.; TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–2015
4. Wallentin L, Becker RC, Budaj A, et al.; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–1057
5. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008; 29: 21–30
6. Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 2010; 56: 1456–1462
7. Alexopoulos D, Galati A, Xanthopoulou I, et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 2012; 60: 193–199
8. Giorgi MA, Cohen Arazi H, Gonzalez CD, et al. Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Expert Opin Pharmacother 2011; 12: 1285–1295
9. Montalescot G, van ’t Hof AW, Lapostolle F, et al.; ATLANTIC Investigators Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014; 371: 1016–1027
10. Steg PG, van ’t Hof A, Hamm CW, et al.; EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013; 369: 2207–2217
11. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction Circulation 2007; 116: 2634–2653
12. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344–2351
13. Morrison LJ, Verbeek PR, McDonald AC, et al. Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. J Am Med Assoc 2000; 283: 2686–2692
14. Montalescot G, Borentain M, Payot L, et al. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. J Am Med Assoc 2004; 292: 362–366
15. Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012; 5: 797–804
16. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013; 61: 1601–1606
17. Valgimigli M, Tebaldi M, Campo G, et al.; FABOLUS PRO Investigators. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv 2012; 5: 268–277
18. Räber L, Windecker S. Primary percutaneous coronary intervention and risk of stent thrombosis: a look beyond the HORIZON. Circulation 2011; 123: 1709–1712
19. Montalescot G, Wiviott SD, Braunwald E, et al.; TRITON-TIMI 38 investigators Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373: 723–731
20. Steg PG, James S, Harrington RA, et al.; PLATO Study Group. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010; 122: 2131–2141
21. Høfsten DE, Kelbaek H, Helqvist H, et al. The third DANish study of optimal Acute treatment of patients with ST-segment elevation myocardial infarction: ischemic postconditioning or deferred stent implantation versus conventional primary angioplasty and complete revascularisation versus treatment of culprit lesion only: rationale and design of the DANAMI 3 trial program. Am Heart J 2015;0: 1–9